Camelot Ventures leads Series B funding of Cellerant

SAN CARLOS, California — September 22, 2005 -- Cellerant Therapeutics, Inc. today announced that it has raised $9 million in a second closing of its Series B round, bringing the total to $25 million. The first closing was led by Novel Bioventures, with the participation of Series A stockholders MPM Capital, Allen & Company LLC, and BD Ventures, and new investors CX Venture Group and Amgen founder George Rathmann. Participants in this second closing include Camelot Ventures, George Rathmann and Eminent Venture Capital Corp. "Cellerant is extremely pleased with this second closing of the Series B and the addition of Camelot Ventures and Eminent Venture Capital Corp. to our investor group," said Bruce Cohen, President and Chief Executive Officer of Cellerant. "Since the first close of our Series B, Cellerant has made significant progress in advancing our purified hematopoietic stem cell infusion, CLT-001, toward the clinic for sickle cell disease. We expect that trial to be under way early next year. This Series B funding will allow us to advance the CLT-001 sickle cell program as well as CLT-001 for the treatment of autoimmune diseases and our cell-based product CLT- 008 for the treatment of radiation- and chemotherapy-induced neutropenia."

About Camelot Ventures
Camelot Ventures is a private investment group comprised of entrepreneurs who have enjoyed unparalleled success in their respective businesses. Formed in the beginning of 1999 after successful IPO's and mergers with Fortune 500 companies, the group invests in companies that they can add value to by sharing their collective business experiences. Camelot's network king, operational strengths and industry contacts provide a tremendous advantage to its investment partners and operating companies.

About Cellerant Therapeutics
Cellerant Therapeutics is a commercial-stage company developing a portfolio of products and services focused on the regulation of the hematopoietic (blood-forming) system. Our products are based on adult hematopoietic stem and progenitor cells as both therapeutic agents and targets for drug discovery. Visit our website at